Published in final edited form as:

Cancer Immunol Res. 2014 October ; 2(10): 962–969. doi:10.1158/2326-6066.CIR-14-0059.

Association Studies of Fc γ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831

Nadine Norton^{1,*}, Rebecca M. Olson^{2,*}, Mark Pegram², Kathleen Tenner³, Karla V. Ballman³, Raphael Clynes^{4,#}, Keith L. Knutson^{3,5,#}, and Edith A. Perez^{1,#}

¹Mayo Clinic, Jacksonville, FL

²Stanford University, Stanford, CA

³Mayo Clinic, Rochester, MN

⁴Columbia University, New York, NY

⁵Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL

Abstract

Patients with HER2⁺ breast cancer treated with trastuzumab and chemotherapy have superior survival compared to patients treated with chemotherapy alone. Polymorphisms within *FCGR2A* and *FCGR3A* are associated with binding affinity of natural killer cells to the IgG1 portion of trastuzumab and a polymorphism in *FCGR2B* (I232T) is associated with impaired regulatory activity. The association of these polymorphisms with clinical response among trastuzumab-treated patients is equivocal with both positive and negative associations. We performed genotyping analysis on the *FCGR3A* V158F, *FCGR2A* R131H, and *FCGR2B* I232T genes in 1,325 patients from the N9831 clinical trial. Patients in Arm A (N=419) received chemotherapy only. Patients in Arms B (N=469) and C (N=437) were treated with chemotherapy and trastuzumab, (sequentially in Arm B and concurrently in Arm C). Using log-rank test and Cox proportional hazard models, we compared disease-free survival (DFS) among genotypic groups within pooled Arms B/C. We found no differences in DFS between trastuzumab-treated patients

#Correspondence: Edith A. Perez, MD, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224; Tel: (904) 953-0118; Fax: (904) 953-6233; perez.edith@mayo.edu. Keith L. Knutson, VGTI FL, 9801 SW Discovery Way, Port St. Lucie, FL 34987, kknutson@vgtifl.org; or, Raphael Clynes, P & S 14-434, 630 W168th St. NY, NY 10032 Columbia University Medical Center, New York, NY 10032, rc645@cumc.columbia.edu.

*Equal contribution first authors

Disclosure of Potential Conflicts of Interest: No other conflicts were disclosed by the authors.

Author's Contributions: Conceptions and design: K.L. Knutson, R. Clynes, E.A. Perez

Development of methodology: R. Clynes, M. Pegram, R. Olson, E.A. Perez

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): R. Olson, M. Pegram, K. Tenner, K.V. Ballman, K.L. Knutson, E.A. Perez

Analysis and interpretation of data (e.g. statistical analysis, biostatistics, computational analysis): N. Norton, R. Olson, K. Tenner, K.V. Ballman, K.L. Knutson, E.A. Perez

Writing, review, and/or revision of the manuscript: N. Norton, R. Olson, M. Pegram, K. Tenner, K.V. Ballman, K.L. Knutson, R. Clynes, E.A. Perez

Administrative, technical, or material support (i.e. reporting or organizing data, constructing databases): Tenner, K.V. Ballman, K.L. Knutson, N. Norton

Study supervision: K.L. Knutson, R. Clynes, E.A. Perez

who had the *FCGR3A* 158 V/V and/or *FCGR2A* 131 H/H high affinity genotypes and patients without those genotypes. Furthermore, there was no significant interaction between *FCGR3A* and *FCGR2A* and treatment. However, there was a difference in DFS for *FCGR2B* I232T with I/I patients deriving benefit from trastuzumab ($p<0.001$) compared to the T carriers who did not ($p=0.81$). The interaction between *FCGR2B* genotype and treatment was statistically significant ($p=0.03$). Our analysis did not reveal an association between Fc γ R high affinity genotypes and outcomes. However, it appears that the *FCGR2B* inhibitory gene may be predictive of adjuvant trastuzumab benefit.

Keywords

Breast cancer; HER2; adjuvant trastuzumab; Fc gamma; polymorphism

Introduction

In the adjuvant setting, patients with HER2 overexpression or amplification (HER2⁺) breast cancer treated with trastuzumab along with chemotherapy have superior disease-free and overall survival compared to patients treated with chemotherapy alone (1-4). However, trastuzumab effectiveness is limited as approximately 20% of adjuvant patients develop tumor relapse within 10 years of receiving treatment (1). In the metastatic setting, only ~25-30% of patients derive significant tumor shrinkage after single agent trastuzumab treatment, which is improved to 50-60% upon the addition of chemotherapy (5).

Understanding the mechanism of action of trastuzumab and chemotherapy is essential to better identify those patients most likely to respond to treatment and potentially to better engineer the drug itself. One of the accepted mechanisms of action is Fc γ receptor (Fc γ R)-dependent antibody-dependent cellular cytotoxicity (ADCC) mediated by various immune effectors such as macrophages and natural killer cells (5-9). ADCC occurs when the Fc portion of the tumor-bound antibody is recognized by the Fc γ Rs (10). In mice deficient in activating Fc γ R genes the antitumor effects of trastuzumab are significantly blunted (11). Consistent with these observations, engineered anti-HER2 antibodies with disabled Fc domains fail to induce tumor responses *in vivo*, despite retained HER2 binding and growth inhibition *in vitro*. Conversely, antitumor antibodies are 10-fold more effective in mice deficient in inhibitory Fc γ Rs and antitumor antibody potency is greatly increased by engineering Fc domains to antibody that binds activating Fc receptors with greater avidity than inhibitory Fc receptors (11).

Some common single nucleotide polymorphisms (SNPs) in the coding regions of the Fc γ R genes have been associated with differential antibody-binding affinities and functional outcomes. A coding polymorphism, V158F, located in the extracellular domain of the Fc γ RIIIa and in an area that directly interacts with the lower hinge region of IgG1, is known to impact binding (12, 13). The histidine allelic variant at amino acid position 131 (H131) in the Fc γ RIIIa extracellular domain confers higher binding affinity than the arginine (R131) variant (14). An *in vitro* study of these polymorphisms using peripheral blood mononuclear cells (PBMC) subsequently demonstrated that PBMCs homozygous for H131 or V158

demonstrated significantly higher trastuzumab-mediated cytotoxicity than PBMCs with other genotypes (15). A third functional polymorphic allele encodes a loss of function variant of the inhibitory receptor, FcγRIIb (I232T). The 232T variant is unable to associate with lipid rafts and is therefore strongly impaired in its negative regulatory activity (16, 17).

Associations of FcγR gene polymorphisms with clinical response among trastuzumab-treated patients have been equivocal, some finding positive associations (15, 18) while others finding no associations (19). A study of 54 patients with HER2⁺ metastatic breast cancer by Musolino and colleagues reported a better objective response rate (ORR) in patients with the *FCGR3A* 158 V/V genotype as compared to patients with V/F and F/F genotypes (15). This study also showed a significantly higher response to trastuzumab therapy in patients with *FCGR3A* 158 V/V genotype and/or *FCGR2A* 131 H/H genotype and when combining both favorable 158 V/V and 131 H/H genotypes, progression-free survival (PFS) was significantly longer than for patients without either genotype. In some agreement with the Musolino study, Tamura and colleagues reported a non-statistically significant trend in a smaller cohort of 35 HER2⁺ patients with metastatic breast cancer with *FCGR3A* 158 V/V patients having a higher ORR than V/F and F/F patients (18). They also observed a significantly higher ORR and PFS period, in patients with *FCGR2A* 131 H/H genotypes compared to H/R and R/R genotypes. In contrast to these studies, two other studies found no association between FcγRs with responses in the metastatic setting (19, 20). The contradictory results of these studies suggest that larger sample sizes are required to ascertain the role of FcγRs, which is now becoming a possibility with the maturation of several ongoing and recently completed adjuvant trials.

To date, the largest study of FcγR polymorphisms and clinical responses to trastuzumab involves genotyping of patients in the adjuvant trastuzumab-chemotherapy study BCIRG-006, which had DNA available from 1,286 patients (19). In that study, Hurvitz and colleagues reported that there was no association between *FCGR3A* and/or *FCGR2A* genotypes and trastuzumab efficacy or disease-free survival (DFS) in patients treated with trastuzumab. Despite the improved sample size, the cohort of trastuzumab patients genotyped in that study appeared to have had little trastuzumab benefit relative to the control arm, limiting power to detect associations with survival, meriting further investigations. Thus, in the present study, we aimed to determine whether the clinical benefit of trastuzumab is associated with polymorphisms in the FcγR genes in the well-powered N9831, adjuvant trastuzumab cohort, with long-term follow-up duration (1). As in the Hurvitz study, we genotyped the two polymorphisms associated with receptor affinity, (*FCGR3A*, *FCGR2A*) but in addition, we also genotyped the inhibitory polymorphism (*FCGR2B* I232T) in 1,325 patients with HER2⁺ breast cancer.

Materials and Methods

Patient population

Patients in the N9831 trial (n=2932), were required to have histologically confirmed adenocarcinoma of the breast with 3+ immunohistochemical staining for HER2 or amplification of the HER2 gene by fluorescence *in situ* hybridization (≥ 2.0 ratio) and with either lymph node-positive or high-risk lymph node-negative disease to be eligible for the

study (1). The N9831 trial had 3 treatment arms. In Arm A patients were treated with doxorubicin and cyclophosphamide every 3 weeks for 4 cycles followed by weekly paclitaxel for 12 weeks; in Arm B patients received sequential trastuzumab treatment with doxorubicin and cyclophosphamide every 3 weeks for 4 cycles, followed by weekly paclitaxel for 12 weeks, followed by 52 weeks of weekly trastuzumab; and in Arm C patients received concurrent trastuzumab treatment, doxorubicin and cyclophosphamide every 3 weeks for 4 cycles, followed by weekly paclitaxel plus concurrent trastuzumab for 12 weeks, followed by 40 more weeks of weekly trastuzumab.

Enrollment to N9831 closed in May of 2005. DNA sample collection was not included in the original study design and was added as addendum 16 in November 2005. DNA samples from 1,325 patients (45% of the full N9831 cohort) were subsequently collected and genotyped for polymorphisms in the *FcγR* genes according to a protocol that was written and approved by the Mayo Clinic Institutional Review Board with written informed consent. DNA samples were not available from 1,607 patients in the N9831 trial, before the addendum to extract germ line DNA.

Genotyping assays

Germline DNA samples were genotyped at Stanford University (Pegram laboratory) for three SNPs in the *FcγR* genes as follows: *FCGR3A* V158F (rs396991), *FCGR2A* R131H (rs1801274), and *FCGR2B* I232T (rs1050501). For each SNP, genotyping was performed with TaqMan real-time PCR assays (Applied Biosystems, Foster City, CA). *FCGR3A* V158F and *FCGR2A* R131H were Taqman assays on demand (C-25815666-10 and C-9077561-20, respectively). The *FCGR2B* I232T polymorphism was determined using a custom TaqMan SNP Genotyping Assay (Applied Biosystems) with the following primers: sense 5'-CCTAGCTCCCAGCTCTTCAC-3' and antisense 5'-CCACTACAGCAGCAACAATGG-3'. TaqMan reactions were set up in 25μL volumes as per the manufacturer's instructions (Applied Biosystems, Foster City, CA), with 10ng DNA. Thermal cycling conditions were initial denaturation step at 95°C for 10 minutes, followed by 50 cycles of denaturation at 92°C for 15 seconds, and annealing/extension step at 60°C for 1 minute. All samples were run in duplicate. Each reaction plate included a triplicate non-template control and internal positive controls. Allelic discrimination was performed with an ABI Prism 7900HT Sequence Detector system using SDS 1.2.3 Software (Applied Biosystems, Foster City, CA). Human DNA specimens (NA00131, NA00607, NA00893) purchased from the Coriell Institute for Medical Research were used as positive controls for each SNP.

Statistical Analysis

The primary goal was to determine if DFS differed among genotypic groups for three polymorphisms in the *FcγR* genes in patients treated with trastuzumab; Arms B and C were pooled for this analysis. DFS was defined as the time from registration to the first disease-related event, which includes a local, regional, or distant breast cancer recurrence; contralateral breast cancer; a new primary cancer (except squamous or basal cell carcinoma of the skin, carcinoma *in situ* of the cervix, or lobular carcinoma *in situ* of the breast); or death from any cause (1). Kaplan-Meier curves were generated for groups of patients based

on treatment arm and/or genotype information and compared with a log-rank test. Cox proportional hazard models were used to generate a point estimate and corresponding 95% confidence intervals (CIs) to estimate hazard ratios (HRs). Specific comparisons were made between genotypic groups within treatment arms and between treatment arms within genotypic groups. A test for an interaction between treatment arm and genotypic group was performed by including the interaction variable and main effects, in a Cox model. Comparisons of variables among the genotypic groups were made with a chi-square test for categorical variables and two-sample t-test (or ANOVA for more than 2 groups) for continuous variables. Exact tests of Hardy-Weinberg equilibrium (21) and linkage disequilibrium values of D' and r^2 were determined in Haploview (21). Analyses were performed with SAS v9.3 and p-values less than 0.05 were considered significant.

Results

Genotyping quality control

DNA was available and genotyped in 1,325 patients from 2,932 (45%) patients in the N9831 trial. The genotype success rate was 100% for 1,325 samples typed in *FCGR3A* and *FCGR2A*, and 99.8% for *FCGR2B*. Genotype distributions were within Hardy-Weinberg Equilibrium (HWE) for *FCGR3A* V158F and *FCGR2A* R131H ($p=0.77$ and $p=0.64$, respectively). We observed a slight excess of homozygous genotypes at the *FCGR3B* I232T SNP, HWE $p=0.02$. Approximately one-third of the DNA samples were genotyped in duplicate with 100% concordance.

Patient population

Only minor differences were observed for clinical and pathological features of genotyped patients treated with trastuzumab (Arms B and C) and patients treated with chemotherapy only (Arm A) (Table 1). Patients genotyped for FcγR gene polymorphisms in Arms B/C showed superior DFS compared to patients in Arm A. At 8 years following randomization, survival in patients in combined Arms B and C was 84.6% (95% CI: 82.2% to 87.1%), whereas in Arm A survival was 76.0% (95% CI: 72.0% to 87.1%; Fig. 1A). The patient subset from which DNA samples were available for analysis, (resulting from a protocol addendum to re-consent patients for an additional blood draw for germ line DNA extraction in 2005) demonstrated superior DFS relative to the 1,607 patients from whom DNA samples were not available for analysis (Fig. 1B). A breakdown of tumor and patient characteristics in the genotyped cohort versus the non-genotyped cohort are presented in supplementary table 1. The non-genotyped cohort had a greater proportion of patients treated on Arm A, was slightly younger, had greater nodal disease, had larger tumors, and had a smaller proportion of hormone receptor positive tumors compared to the genotyped cohort.

Of the individuals genotyped in this study, race was reported as: White 88.4%; Black or African American 5.5%, Asian 2%, and Unknown/not given 4.1%. We examined differences in patient demographics and tumor characteristics between each genotype group for each polymorphism (Supplementary Tables S2-S4). No meaningful differences were observed between genotypic groups for polymorphisms in *FCGR3A* and *FCGR2A*. For *FCGR2B* I232T, however, we observed a slight excess of 232T homozygous genotypes in

non-Whites compared to Whites, $p=0.004$, (Supplementary Table S4), although, as we have noted that the number of 232T homozygotes is small, ($n=30$).

FcγR gene allele frequencies and linkage disequilibrium

Allele frequencies and linkage disequilibrium measures for *FCGR3A* V158F and *FCGR2A* R131H were comparable to those previously reported by Hurvitz and colleagues (19). The minor allele frequencies (MAF) across 1,325 individuals for *FCGR3A* V158F, *FCGR2A* R131H, and *FCGR2B* I232T were $V=0.354$, $R=0.497$ and $T=0.124$. *FCGR3A* V158F and *FCGR2A* R131H map 34.8 kilobases apart and given the previous reports of positive association of both the 158V and 131H variants, we tested the degree of linkage disequilibrium between these loci. We found that the linkage disequilibrium was low, $D' = 0.37$ and $r^2 = 0.07$, suggesting these variants are not correlated despite their close physical proximity.

We further examined allele frequencies of each polymorphism by race. *FCGR3A* V158F minor allele frequencies were 158V=0.355, 0.377 and 0.389 in Whites ($N=1,170$), African Americans ($N=73$) and Asians ($N=27$), respectively. *FCGR2A* MAFs were 131R=0.495, 0.479 and 0.481 in Whites, African Americans and Asians, respectively. *FCGR2B* I232T showed a significant difference in allele frequency by race with MAFs (232T) of 0.118, 0.171 and 0.185 in Whites, African Americans and Asians, respectively ($p=0.019$, White vs. non-White). The genotypic distribution of *FCGR2B* I232T was within HWE for Whites and African Americans, $p=0.24$ in both. In the Asian group, genotype distributions were not in HWE, $p=0.04$, with an excess of T homozygotes. This is in line with published data in which the frequency of the *FCGR2B* 232T variant is increased in African and Asian populations, broadly corresponding to areas where malaria is endemic (22). It is possible that the observed 232T excess in our African American and Asian populations and deviation from HWE in Asians, results from positive selection of the 232T variant. Measures of linkage disequilibrium for each marker combination showed some variation by race, but linkage disequilibrium was low to moderate in all cases.

Association of genotype with DFS in patients treated with trastuzumab

There were no significant differences in DFS among the genotypic groups for *FCGR3A*, *FCGR2A*, and *FCGR2B* for patients treated with trastuzumab (Figures 2A-C). Furthermore, there was no significant difference in DFS between patients who were homozygous for *FCGR3A* V/V and/or homozygous for *FCGR2A* H/H and patients who were not: HR = 1.01 (95% CI: 0.72 to 1.41, $p=0.96$). Our results differ from published reports that did find an association with DFS and patients who were *FCGR2A* H/H and/or *FCGR3A* V/V (15, 18). An analysis of Arms B and C separately also did not find significant associations of genotypic groups *FCGR3A*, *FCGR2A*, and *FCGR2B* (Supplemental Figures S1A-C).

Impact of genotype on trastuzumab effect

Stratified Cox models were used to compare the DFS between trastuzumab-treated patients (Arms B/C) and patients not treated with trastuzumab (Arm A) within each genotypic group for *FCGR3A*, *FCGR2A*, and *FCGR2B* (Figure 3). For *FCGR3A* and *FCGR2A*, the trastuzumab effect appears to be similar among the different genotypic groups. Non-

significant p-values for the tests for interaction of treatment arms (A vs. B/C) and *FCGR3A* and *FCGR2A* genotypes confirmed this observation. However, it appears as though there might be an interaction between treatment and *FCGR2B* genotype from Figure 4.

Given the relatively few patients with the T/T genotype for *FCGR2B*, an analysis was performed comparing patients who were I/I homozygous to those who were T carriers (I/T and T/T). The test for interaction between treatment arms (A vs. B/C) and *FCGR2B* genotype (I/I versus T carrier) was significant ($p=0.03$). Figure 4A shows that *FCGR2B* I/I patients treated with trastuzumab had better DFS compared to those not treated with trastuzumab ($p < 0.0001$). However, it does not appear as though DFS differed between T carriers who were and were not treated with trastuzumab ($p=0.81$, Figure 4B), and T-carriers who received chemotherapy only showed similar survival to I/I homozygotes who received chemotherapy plus trastuzumab. Exploratory Kaplan Meier analysis of patients treated with chemotherapy only, showed improved survival in T-carriers compared to I/I homozygotes, $p=0.01$.

Discussion

Common genetic variants in the Fc γ R genes *FCGR3A* (V158F) and *FCGR2A* (R131H) are associated with affinity for the monoclonal antibody trastuzumab *in vitro*, (12-14), while the I232T variant is associated with loss of function in the inhibitory receptor encoded by *FCGR2B* (16). A positive association of these genetic variants with clinical outcome in patients treated with trastuzumab would support the use of genotyping to preselect patients most likely to respond to trastuzumab treatment and further engineering of monoclonal antibodies with increased affinity for the Fc γ Rs. Suggestions of positive associations with clinical outcome to date have arisen from multiple, small studies of patients treated in the metastatic ($n=35-54$) and neoadjuvant ($n=15$) settings (15, 18).

Our study design tested for association of three Fc γ R polymorphisms with disease-free survival in the N9831 clinical trial of patients with early stage HER2-positive breast cancer treated with chemotherapy alone (Arm A) or chemotherapy in combination with trastuzumab (Arms B/C). We did not find association of the *FCGR2A* and *FCGR3A* genes for any genotype or genotypic combination with improved disease-free survival. However, *FCGR2B* I/I patients showed superior DFS in the trastuzumab arms as compared to I/I patients in the chemotherapy only arm. In contrast, patients who carried the T-allele did not show any benefit from trastuzumab and demonstrated survival nearly the same as I232 (I/I) patients that received trastuzumab. This is important because it suggests that the I232 variant may be predictive of trastuzumab benefit or that the T-allele is an independent DFS predictor in breast cancer patients treated with chemotherapy alone.

We can only speculate on the biologic reasons as to why trastuzumab treated and non-treated T carriers had survival similar to trastuzumab-treated I/I homozygotes. Fc γ R2B plays an inhibitory role in the immune response and the minor allele (232T) results in loss of function of the inhibitory response. Loss of the suppressive function results in increased resistance to infection (e.g. malaria) as well as increased susceptibility to autoimmunity (e.g. systemic lupus erythematosus) (22). Thus, one possibility is that the T-allele could be

associated with enhanced anti-tumoral immunity, possibly including a natural endogenous trastuzumab-like response. This natural response has been observed in some cases in HER2-positive breast cancer (23). Hence, we would predict T carriers to have good survival and not respond to trastuzumab because they already demonstrate natural endogenous trastuzumab-like immune response. In I/I patients, we would predict the addition of trastuzumab could compensate for the lack of natural response, thus improving DFS.

Our study of 1,325 patients from N9831 is partially in agreement with that of Hurvitz and colleagues, which genotyped the *FCGR3A* (V158F) and *FCGR2A* (R131H) polymorphisms in ~1,200 patients from the BCIRG-006 adjuvant trastuzumab-based study. Taking this into consideration our study is highly relevant for three reasons. First, the subset of BCIRG-006 patients that were genotyped showed little benefit from trastuzumab (HR, 0.842; P = 0.1925). Secondly, the genotypic data for *FCGR3A* polymorphism deviated significantly from that expected by Hardy-Weinberg equilibrium, $p < 0.001$. The lack of genotyping in a control (healthy population) cohort made it difficult to determine if this deviation resulted from systematic genotyping error or putative genetic association with breast cancer. In our similarly-sized cohort, both significant benefit from trastuzumab (Arm A vs Arms B/C, $p < 0.001$) in the subset of individuals genotyped for the FcγR polymorphisms and non-deviation from HWE for either the *FCGR3A* or *FCGR2A* polymorphism were observed. Similarly, our MAFs and measures of linkage disequilibrium between the *FCGR3A* and *FCGR2A* polymorphisms are also in agreement with Hurvitz and colleagues, suggesting that the polymorphisms genotyped in these studies may have little or no effect on clinical outcome in patients treated with trastuzumab. Thirdly, our study differed from that of Hurvitz and colleagues, as we also evaluated for impact of the inhibitory FcγR polymorphism *FCGR2B* I232T.

There are a number of limitations to our study that might explain a lack of association of FcγR high affinity variants with outcome. Firstly, germ line DNA collection was not included in the original study design, but as a protocol addendum 5 months after the close of enrollment, hence DNA was available for only 1325/2932 (45%) of patients. The subset of genotyped individuals showed significant benefit from trastuzumab to the same degree as the full N9831 cohort, but we also observed that patients in the genotyped subset showed superior DFS compared to patients who did not provide or consent for DNA analysis, $p < 0.001$. It is possible that the non-genotyped cohort had a more aggressive form of disease because this cohort had a greater proportion of patients treated on Arm A, was slightly younger, had greater nodal disease, had larger tumors, and had a smaller proportion of hormone receptor positive tumors compared to the genotyped cohort. This chance bias towards improved clinical outcome in the genotyped cohort could have potentially masked modest genotypic effects on outcome. Secondly, despite the large sample size, the total number of events in the genotyped cohort was 268, (160 in the trastuzumab Arms and 108 in the chemotherapy-only Arm), which when further broken down by genotype would limit the power to detect small or modest associations. This is also of relevance to the most significant finding of the study with the *FCGR2B* I232T variant. Within the trastuzumab-containing arms, only 35 events were observed among patients carrying the 232T variant. Thirdly, our choice of polymorphisms was based on previous published associations with metastatic breast cancer, neoadjuvant breast cancer and *in vitro* functional assays. There

remains the possibility that these polymorphisms are associated with survival difference only in certain treatment settings such as the metastatic and perhaps neoadjuvant setting as reported by Musolino and colleagues (15). However, this argument is tempered by the study by Hurvitz and colleagues, which also examined patients with metastatic cancer and found no association of progression-free survival with the polymorphisms. Alternatively, as Carlotti and colleagues have postulated in the rituximab setting, the effects of the Fc γ R variants may only be relevant when antibodies are used as monotherapy (24). Finally, we did not perform comprehensive genotyping across the Fc γ R genomic locus, and there are potentially other genetic variants in this region that could influence response to trastuzumab or moderate the effect of the variants selected in this study, such as the three copy number variable regions spanning the *FCGR3A*, *FCGR2A*, *FCGR2C* and *FCGR2B* genes (25).

In conclusion, our data did not identify any genetic association of *FCGR2A* and *FCGR3A* high affinity alleles with superior DFS in patients treated with trastuzumab. While this finding does not preclude a role of these Fc γ Rs, it does suggest that these polymorphisms alone have small, if any, effect on clinical outcome of trastuzumab in the adjuvant setting when delivered in combination or immediately following chemotherapy. However, our observation of *FCGR2B* as predictive of benefit to trastuzumab or alternatively, as an independent predictor of DFS in patients treated with chemotherapy alone has not been tested in other comparable studies and warrants further investigation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by grants to E.A.P, K.L.K, and R. C. from the NCI/NIH (Grant R01-CA152045), and the Susan G. Komen for Cure Foundation (Grant KG101016). This work uses data from NCCTG trial N9831 which was supported, in part, by a grant from the NCI/NIH (CA25224) and Genentech. The authors gratefully acknowledge the technical assistance of Courtney Erskine and Marshall Behrens with help for sample access and aliquoting. Preliminary reports from this study were presented at the AACR Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications- Oct 3-6, 2013; San Diego, CA (abstract 6649_1).

Edith Perez is the recipient of grants from Genentech.

References

1. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE, et al. Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data from NCCTG N9831 and NSABP B-31. *J Clin Oncol*. 2011; 29:3366–73. [PubMed: 21768458]
2. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med*. 2011; 365:1273–83. [PubMed: 21991949]
3. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med*. 2005; 353:1673–84. [PubMed: 16236738]
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med*. 2005; 353:1659–72. [PubMed: 16236737]

5. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. *J Clin Oncol*. 2013; 31:1157–63. [PubMed: 23382472]
6. Baselga J, Gianni L, Geyer C, Perez EA, Riva A, Jackisch C. Future options with trastuzumab for primary systemic and adjuvant therapy. *Semin Oncol*. 2004; 31:51–7. [PubMed: 15490375]
7. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. *Curr Opin Immunol*. 2007; 19:239–45. [PubMed: 17291742]
8. Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA, et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. *J Transl Med*. 2008; 6:25. [PubMed: 18485193]
9. Whenham N, D'Hondt V, Piccart MJ. HER2-positive breast cancer: from trastuzumab to innovative anti-HER2 strategies. *Clin Breast Cancer*. 2008; 8:38–49. [PubMed: 18501058]
10. Nimmerjahn F, Ravetch JV. Fcγ receptors: old friends and new family members. *Immunity*. 2006; 24:19–28. [PubMed: 16413920]
11. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. *Nat Med*. 2000; 6:443–6. [PubMed: 10742152]
12. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc fragment-Fc γ₃ complex. *Nature*. 2000; 406:267–73. [PubMed: 10917521]
13. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcγ receptor in complex with Fc. *J Biol Chem*. 2001; 276:16469–77. [PubMed: 11297532]
14. Warmerdam PA, van de Winkel JG, Vlug A, Westerdal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc γ₂ receptor II is critical for human IgG2 binding. *J Immunol*. 1991; 147:1338–43. [PubMed: 1831223]
15. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. *J Clin Oncol*. 2008; 26:1789–96. [PubMed: 18347005]
16. Baerenwaldt A, Nimmerjahn F. Immune regulation: FcγRIIB--regulating the balance between protective and autoreactive immune responses. *Immunol Cell Biol*. 2008; 86:482–4. [PubMed: 18504454]
17. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. *Nat Rev Immunol*. 2008; 8:34–47. [PubMed: 18064051]
18. Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, et al. FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. *Ann Oncol*. 2011; 22:1302–7. [PubMed: 21109570]
19. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, et al. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. *Clin Cancer Res*. 2012; 18:3478–86. [PubMed: 22504044]
20. Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, et al. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. *Oncology*. 2012; 83:218–27. [PubMed: 22906996]
21. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics*. 2005; 21:263–5. [PubMed: 15297300]
22. Clatworthy MR, Willcocks L, Urban B, Langhorne J, Williams TN, Peshu N, et al. Systemic lupus erythematosus-associated defects in the inhibitory receptor FcγRIIB reduce susceptibility to malaria. *Proc Natl Acad Sci U S A*. 2007; 104:7169–74. [PubMed: 17435165]
23. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. *Breast Cancer Res Treat*. 2000; 62:245–52. [PubMed: 11072789]
24. Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, et al. FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's

- lymphoma patients treated with sequential CHOP and rituximab. *Haematologica*. 2007; 92:1127–30. [PubMed: 17650444]
25. Niederer HA, Willcocks LC, Rayner TF, Yang W, Lau YL, Williams TN, et al. Copy number, linkage disequilibrium and disease association in the FCGR locus. *Hum Mol Genet*. 2010; 19:3282–94. [PubMed: 20508037]

Figure 1. The therapeutic benefit of trastuzumab-containing regimens was observed in N9831 patients who provided DNA specimens for genetic analysis

A, Kaplan-Meier (KM) analysis of DFS by treatment group with Arms B and C combined. The inset numbers shown are the numbers of individuals considered at risk at the respective time points in each cohort. B, KM analysis of DFS in patients who provided DNA for FcγR analysis (FcγR cohort) compared to patients who did not provide DNA and for whom genotyping data were not available.

Figure 2. DFS was not improved for any genotypic group in the trastuzumab-containing regimens

Kaplan-Meier analyses of DFS by genotype group for each of the three FcγR genes examined: (A) *FCGR3A* V158F, (B) *FCGR2A* R131H and (C) *FCGR2B* I232T.

Figure 3. Hazard ratios did not differ by genotype in Arm A versus Arms B/C

Hazard ratios (HRs) of Arm B/C individuals compared to Arm A patients as calculated by Cox regression analysis in the full N9831 cohort, N9831 subset genotyped for the FcγR cohort and each genotype.

Figure 4. *FCGR2B* 232 T carriers may not benefit from the inclusion of trastuzumab into their adjuvant chemotherapy regimen

Kaplan-Meier analyses of DFS by genotype group for both Arms A and B/C (A) *FCGR2B* 232 I/I homozygote genotype and (B) *FCGR2B* 232 T carrier.

Table 1
Patient and Clinical Characteristics

	Arm A (N=419)	Arm B/C (N=906)	p value
Age			0.75
N	419	906	
Mean (SD)	50.0 (10.0)	50.2 (10.3)	
Median	50	50	
Q1, Q3	43.0, 57.0	43.0, 57.0	
Range	(27.0-80.0)	(22.0-82.0)	
Age Group			0.82
<40	62 (15%)	147 (16%)	
40-49	140 (33%)	278 (31%)	
50-59	145 (35%)	316 (35%)	
60	72 (17%)	165 (18%)	
Menopausal Status			0.68
Premenopausal or <50	223 (53%)	471 (52%)	
Postmenopausal or ≥50	196 (47%)	435 (48%)	
Breast Surgery			0.5
Breast Sparing	177 (42%)	365 (40%)	
Mastectomy	242 (58%)	541 (60%)	
Positive nodes			0.99
axdis 1-3 positive	164 (39%)	348 (38%)	
axdis 4-9 positive	107 (26%)	246 (27%)	
axdis 10+ positive	47 (11%)	99 (11%)	
pos sent node	35 (8%)	80 (9%)	
neg sent node	40 (10%)	82 (9%)	
neg axdis	26 (6%)	51 (6%)	
Receptor status			0.4
ER Positive and/or PR Positive	226 (54%)	511 (56%)	
Other	193 (46%)	395 (44%)	
Tumor Size			0.61
2.0 cm	170 (41%)	394 (43%)	
2.0-5.0 cm	218 (52%)	447 (49%)	
>5.0 cm	31 (7%)	65 (7%)	
Histology			0.23
Ductal	390 (93%)	860 (95%)	
Other	28 (7%)	46 (5%)	
Missing	1	0	
Tumor Grade			0.61
High	301 (73%)	644 (72%)	
Low/Intermediate	111 (27%)	254 (28%)	
Missing	7	8	

	Arm A (N=419)	Arm B/C (N=906)	p value
Tumor Stage			0.61
1	170 (41%)	394 (43%)	
2	218 (52%)	447 (49%)	
3	31 (7%)	65 (7%)	
N Stage			0.34
0	66 (16%)	133 (15%)	
1	334 (80%)	722 (80%)	
2	18 (4%)	51 (6%)	
3	1 (0%)	0 (0%)	
Agent			0.52
None	193 (46%)	396 (44%)	
Other	77 (18%)	158 (17%)	
Tamoxifen	149 (36%)	352 (39%)	

axdis = axillary lymph node dissection

pos sent = positive sentinel node dissection

neg sent = negative sentinel node dissection

neg axdis = negative axillary node